The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Acromegaly


High impact information on Acromegaly

  • Successful pregnancy in a previously infertile woman treated with SMS-201-995 for acromegaly [6].
  • We measured the ability of plasma extracts from patients with acromegaly to inhibit the binding of ouabain to the sodium pump in normal red cells and to inhibit the enzymatic activity (sodium-potassium-ATPase) of the sodium pump in membrane preparations from normal kidneys [7].
  • Although bromocriptine, a dopamine receptor agonist, is now widely used in the treatment of acromegaly, there have been no controlled trials of its biochemical or clinical effects on this disorder [8].
  • Measurement of somatomedin-C appears to provide a reliable means for confirming the diagnosis of acromegaly and of clinical disease activity than measurement of growth hormone concentrations [9].
  • Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly [10].

Chemical compound and disease context of Acromegaly


Biological context of Acromegaly


Anatomical context of Acromegaly

  • Growth hormone-releasing factors (GRF's) from two human pancreatic tumors (hpGRF's) that caused acromegaly and from the rat hypothalamus ( rhGRF ) were recently isolated and characterized [22].
  • Thyroid volume and serum thyroglobulin levels in patients with acromegaly: correlation with plasma insulin-like growth factor I levels [23].
  • In this investigation, the pituitary glands of eight patients with CNC and acromegaly [age, 22.9+/-11.6 yr (mean +/- SD)] were studied histologically [24].
  • This study examined the effects of acromegaly treatment on adipose tissue LPL [25].
  • Our data demonstrate that patients with long-term acromegaly have normal sympathetic activity in the skeletal muscle in the basal, postabsorptive state and normal increments in NE spillover in response to the sympatho-excitatory effect of insulin [26].

Gene context of Acromegaly


Analytical, diagnostic and therapeutic context of Acromegaly


  1. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Ng, S.T., Zhou, J., Adesanya, O.O., Wang, J., LeRoith, D., Bondy, C.A. Nat. Med. (1997) [Pubmed]
  2. Bromocriptine for an acromegalic patient. Improvement in cardiac function and carpal tunnel syndrome. Luboshitzky, R., Barzilai, D. JAMA (1980) [Pubmed]
  3. Growth hormone-releasing peptides and their analogs. Camanni, F., Ghigo, E., Arvat, E. Frontiers in neuroendocrinology. (1998) [Pubmed]
  4. Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. Zapf, J., Walter, H., Froesch, E.R. J. Clin. Invest. (1981) [Pubmed]
  5. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Grunstein, R.R., Ho, K.K., Sullivan, C.E. Ann. Intern. Med. (1994) [Pubmed]
  6. Successful pregnancy in a previously infertile woman treated with SMS-201-995 for acromegaly. Landolt, A.M., Schmid, J., Wimpfheimer, C., Karlsson, E.R., Boerlin, V. N. Engl. J. Med. (1989) [Pubmed]
  7. Evidence of an endogenous digitalis-like factor in the plasma of patients with acromegaly. Deray, G., Rieu, M., Devynck, M.A., Pernollet, M.G., Chanson, P., Luton, J.P., Meyer, P. N. Engl. J. Med. (1987) [Pubmed]
  8. No effect of bromocriptine in acromegaly: a controlled trial. Lindholm, J., Riishede, J., Vestergaard, S., Hummer, L., Faber, O., Hagen, C. N. Engl. J. Med. (1981) [Pubmed]
  9. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. Clemmons, D.R., Van Wyk, J.J., Ridgway, E.C., Kliman, B., Kjellberg, R.N., Underwood, L.E. N. Engl. J. Med. (1979) [Pubmed]
  10. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Kopchick, J.J., Parkinson, C., Stevens, E.C., Trainer, P.J. Endocr. Rev. (2002) [Pubmed]
  11. Insulin action in human adipose tissue in acromegaly. Bolinder, J., Ostman, J., Werner, S., Arner, P. J. Clin. Invest. (1986) [Pubmed]
  12. Primary structures of three human pancreas peptides with growth hormone-releasing activity. Esch, F.S., Böhlen, P., Ling, N.C., Brazeau, P.E., Wehrenberg, W.B., Guillemin, R. J. Biol. Chem. (1983) [Pubmed]
  13. Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones. Veysey, M.J., Thomas, L.A., Mallet, A.I., Jenkins, P.J., Besser, G.M., Wass, J.A., Murphy, G.M., Dowling, R.H. Gut (1999) [Pubmed]
  14. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Clemmons, D.R., Underwood, L.E., Ridgway, E.C., Kliman, B., Kjellberg, R.N., Van Wyk, J.J. Am. J. Med. (1980) [Pubmed]
  15. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. Caron, P., Morange-Ramos, I., Cogne, M., Jaquet, P. J. Clin. Endocrinol. Metab. (1997) [Pubmed]
  16. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. Freda, P.U., Shen, W., Heymsfield, S.B., Reyes-Vidal, C.M., Geer, E.B., Bruce, J.N., Gallagher, D. J. Clin. Endocrinol. Metab. (2008) [Pubmed]
  17. Bone mineral density and parameters of bone metabolism in patients with acromegaly. Kotzmann, H., Bernecker, P., Hübsch, P., Pietschmann, P., Woloszczuk, W., Svoboda, T., Geyer, G., Luger, A. J. Bone Miner. Res. (1993) [Pubmed]
  18. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. O'Connell, T., Clemmons, D.R. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  19. Blood pressure response to an angiotensin II antagonist in patients with acromegaly. Ogihara, T., Hata, T., Maruyama, A., Mikami, H., Nakamaru, M., Okada, Y., Kumahara, Y. J. Clin. Endocrinol. Metab. (1979) [Pubmed]
  20. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. Jaquet, P., Saveanu, A., Gunz, G., Fina, F., Zamora, A.J., Grino, M., Culler, M.D., Moreau, J.P., Enjalbert, A., Ouafik, L.H. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  21. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Heron, I., Thomas, F., Dero, M., Gancel, A., Ruiz, J.M., Schatz, B., Kuhn, J.M. J. Clin. Endocrinol. Metab. (1993) [Pubmed]
  22. Growth hormone-releasing factor stimulates pancreatic enzyme secretion. Pandol, S.J., Seifert, H., Thomas, M.W., Rivier, J., Vale, W. Science (1984) [Pubmed]
  23. Thyroid volume and serum thyroglobulin levels in patients with acromegaly: correlation with plasma insulin-like growth factor I levels. Miyakawa, M., Saji, M., Tsushima, T., Wakai, K., Shizume, K. J. Clin. Endocrinol. Metab. (1988) [Pubmed]
  24. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). Pack, S.D., Kirschner, L.S., Pak, E., Zhuang, Z., Carney, J.A., Stratakis, C.A. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  25. Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase. Simsolo, R.B., Ezzat, S., Ong, J.M., Saghizadeh, M., Kern, P.A. J. Clin. Endocrinol. Metab. (1995) [Pubmed]
  26. Muscle sympathetic nerve activity in patients with acromegaly. Capaldo, B., Lembo, G., Rendina, V., Guida, R., Marzullo, P., Colao, A., Lombardi, G., Saccà, L. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  27. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. Murray, R.D., Kim, K., Ren, S.G., Chelly, M., Umehara, Y., Melmed, S. J. Clin. Invest. (2004) [Pubmed]
  28. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Gorden, P., Comi, R.J., Maton, P.N., Go, V.L. Ann. Intern. Med. (1989) [Pubmed]
  29. Growth hormone and prolactin secretion in acromegaly: correlations between hormonal dynamics and immunocytochemical findings. Bassetti, M., Arosio, M., Spada, A., Brina, M., Bazzoni, N., Faglia, G., Giannattasio, G. J. Clin. Endocrinol. Metab. (1988) [Pubmed]
  30. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion. Moller, D.E., Moses, A.C., Jones, K., Thorner, M.O., Vance, M.L. J. Clin. Endocrinol. Metab. (1989) [Pubmed]
  31. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3. Arosio, M., Garrone, S., Bruzzi, P., Faglia, G., Minuto, F., Barreca, A. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  32. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. Lamberts, S.W., Uitterlinden, P., Verschoor, L., van Dongen, K.J., del Pozo, E. N. Engl. J. Med. (1985) [Pubmed]
  33. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995. Williams, G., Ball, J.A., Burrin, J.M., Joplin, G.F., Bloom, S.R. Lancet (1986) [Pubmed]
  34. Bromocriptine reduces growth hormone in acromegaly. Bell, P.M., Atkinson, A.B., Hadden, D.R., Kennedy, L., Leslie, H., Merrett, J.D., Sheridan, B. Arch. Intern. Med. (1986) [Pubmed]
  35. Acromegaly. Bloom, S.R. Am. J. Med. (1987) [Pubmed]
WikiGenes - Universities